GEN Exclusives

More »

GEN News Highlights

More »
Jun 26, 2007

Intradigm Selects Agilent as Manufacturing Partner for RNAi Oncology Therapeutic

  • Intradigm chose Agilent Technologies to manufacture the active siRNA component of its RNAi therapeutic. In addition, Intradigm selected ICS-283 as its lead RNAi product candidate.

    Under terms of the agreement, Agilent will support the initiation of clinical development for ICS-283. Intradigm expects to initiate trials in 2008.

    ICS-283 is the only systemic RNAi therapeutic in preclinical development against a clinically validated oncology target (vascular endothelial growth factor or VEGF), according to Intradigm. It is a nanoparticle-based compound comprised of multiple siRNAs that target both VEGF and its receptor.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?